CTOs on the Move

Dyno Therapeutics

www.dynotx.com

 
Dynotx.com provides cutting-edge sales and marketing tools for small and medium-sized businesses. Their services include web design, social media management, advertising, and SEO optimization. They aim to help businesses grow and succeed online by prov...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.dynotx.com
  • 343, Arsenal Street
    Watertown, MA USA 02472
  • Phone: 857.242.0593

Executives

Name Title Contact Details

Similar Companies

Denali Therapeutics

Denali Therapeutics Inc. (“Denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. Founding investors include Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund (represented by Crestline Investors).

Mitsubishi Tanabe Pharma Development America

Mitsubishi Tanabe Pharma Development America is a Warren, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Integrated Biomolecule Corporation

Integrated Biomolecule Corporation is a Tucson, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ontera

Our platforms use silicon nanopore chips and proprietary biochemistry to accurately detect and differentiate single molecules. We will help transform point-of-care testing and third generation sequencing.

GigaGen

GigaGen is advancing a pipeline of first-in-class biotherapeutics, including novel oncology antibody drug combinations and the world`s first recombinant polyclonal hyperimmune gammaglobulin. Behind our diverse and growing pipeline is a mission to bring forth a new generation of highly efficacious drugs, driven by an unparalleled understanding of immune dysregulation. Our proprietary antibody discovery technology quickly characterizes every cell in complex immune systems, powering our selection of drug targets, identification of drug candidates and preclinical assessment of efficacy.